Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Masitinib plus riluzole versus placebo plus riluzole in amyotrophic lateral sclerosis
2019-001862-13Phase 3Completed
- Sponsor
- AB Science
- Start
- Feb 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of masitinib in amyotrophic lateral sclerosis (ALS) (3 arms), sponsored by AB Science. Primary endpoint: Absolute change from baseline to week 48 in ALSFRS-R total score. Started Feb 2020; status: completed.
02
Drugs
masitinib
03
Conditions
amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on 2019-001862-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-001862-13.